Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.36 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2289941 | 0.84 | — | — | |
| SCHEMBL19766 | 0.83 | POLB (0.42) | ATMBRD4POLBOPRM1SMN1; SMN2 | |
| SCHEMBL136687 | 0.83 | ATM (0.44) | ATMPOLBOPRM1SMN1; SMN2OPRD1 | |
| SCHEMBL5526295 | 0.81 | BRD4 (0.45) | ATMBRD4POLBOPRM1SMN1; SMN2 | |
| SCHEMBL15106045 | 0.80 | ATM (0.41) | ATMPOLBOPRM1SMN1; SMN2OPRD1 | |
| SCHEMBL17648935 | 0.79 | BRD4 (0.38) | ATMBRD4POLBOPRM1SMN1; SMN2 | |
| SCHEMBL22280417 | 0.79 | ATM (0.41) | ATMPOLBOPRM1SMN1; SMN2OPRD1 | |
| SCHEMBL9043939 | 0.79 | FFAR3 (0.36) | ATMSMN1; SMN2MEN1KMT2A | |
| SCHEMBL60903 | 0.78 | BRD4 (0.41) | ATMBRD4POLBOPRM1SMN1; SMN2 | |
| SCHEMBL265557 | 0.78 | SMN1; SMN2 (0.45) | ATMBRD4POLBOPRM1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466805-B2 | Pharmaceutical compounds | ALMAC DISCOVERY LIMITED (GB) | 2025-11-11 | — | — | US | disclosed |
| WO-2025059577-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS FOR USE AS AKT1 INHIBITORS | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| CN-109790146-B | Pharmaceutical compounds | 阿尔麦克探索有限公司 | 2022-08-23 | — | — | CN | disclosed |
| EP-3490982-B1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LTD (GB) | 2022-04-20 | — | — | EP | disclosed |
| US-20220002264-A1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2022-01-06 | — | — | US | disclosed |
| US-11053213-B2 | Pharmaceutical compounds | ALMAC DISCOVERY LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| US-20190233394-A1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2019-08-01 | — | — | US | disclosed |
| EP-3490982-A1 | PHARMACEUTICAL COMPOUNDS | Almac Discovery Limited (GB) | 2019-06-05 | — | — | EP | disclosed |
| CN-109790146-A | Medical compounds | 阿尔麦克探索有限公司 | 2019-05-21 | — | — | CN | disclosed |
| WO-2018020242-A1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2018-02-01 | — | — | WO | disclosed |
| WO-2011002887-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | SCHERING CORPORATION (US) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466805-B2 | Pharmaceutical compounds | USP19, USP18, UBE2I | ATM 3858/4885BRD4 1653/4885POLB 2873/4885 |
| US-20190233394-A1 | PHARMACEUTICAL COMPOUNDS | USP19, USP18, UBE2I | ATM 3858/4885BRD4 1653/4885POLB 2873/4885 |
| US-20220002264-A1 | PHARMACEUTICAL COMPOUNDS | USP19, USP18, UBE2I | ATM 3858/4885BRD4 1653/4885POLB 2873/4885 |
| US-11053213-B2 | Pharmaceutical compounds | USP19, USP18, UBE2I | ATM 3858/4885BRD4 1653/4885POLB 2873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.